Abstract
Rufloxacin is a new long-acting, once-daily quinolone antibacterial agent. We evaluated inter- and intrasubject variations in pharmacokinetics of rufloxacin following oral administration of 400 mg (two capsules) under controlled conditions, at an interval of 2 weeks (periods I and II), to 12 healthy male subjects. Plasma and urine samples were collected up to 48 h after drug administration. Plasma drug levels determined by bioassay were higher than those measured by high-performance liquid chromatography, indicating that one or more active metabolites were formed. Individual high-performance liquid chromatography plasma rufloxacin concentrations were fitted with a one-compartment open model with first-order input. There were considerable variations in the plasma concentration-time profiles among subjects; for example, the elimination half-life in plasma varied from 14.6 to 95.5 h. However, pharmacokinetic parameters calculated for the two periods did not differ significantly. These results suggest that the intrasubject variation in the pharmacokinetics of rufloxacin is usually small in spite of the considerable intersubject variation.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bennett J. V., Brodie J. L., Benner E. J., Kirby W. M. Simplified, accurate method for antibiotic assay of clinical specimens. Appl Microbiol. 1966 Mar;14(2):170–177. doi: 10.1128/am.14.2.170-177.1966. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Cecchetti V., Fravolini A., Fringuelli R., Mascellani G., Pagella P., Palmioli M., Segre G., Terni P. Quinolonecarboxylic acids. 2. Synthesis and antibacterial evaluation of 7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzothiazine-6-carboxylic acids. J Med Chem. 1987 Mar;30(3):465–473. doi: 10.1021/jm00386a005. [DOI] [PubMed] [Google Scholar]
- Gibaldi M., Levy G., McNamara P. J. Effect of plasma protein and tissue binding on the biologic half-life of drugs. Clin Pharmacol Ther. 1978 Jul;24(1):1–4. doi: 10.1002/cpt19782411. [DOI] [PubMed] [Google Scholar]
- Imbimbo B. P., Imbimbo E., Daniotti S., Verotta D., Bassotti G. A new criterion for selection of pharmacokinetic multiexponential equations. J Pharm Sci. 1988 Sep;77(9):784–789. doi: 10.1002/jps.2600770914. [DOI] [PubMed] [Google Scholar]
- Ravizzola G., Pinsi G., Pirali F., Colombrita D., Foresti I., Peroni L., Turano A. Rufloxacin (MF-934): in vitro and in vivo antibacterial activity. Drugs Exp Clin Res. 1989;15(1):11–15. [PubMed] [Google Scholar]
- Segre G., Cerretani D., Cerri D., Moltoni L. A new tricyclic fluoroquinolone, rufloxacin (MF-934), with interesting antibacterial and pharmacokinetic characteristics. Drugs Exp Clin Res. 1988;14(12):747–754. [PubMed] [Google Scholar]